Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Finger length may offer clues to breast cancer risk

NCT ID NCT07436169

First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 12 times

Summary

This study looked at whether the ratio of index to ring finger length (2D:4D) is different in women with breast cancer compared to healthy women. Researchers measured the fingers of 132 women (79 with breast cancer, 53 without) and checked if the ratio related to tumor markers in the blood. The goal was to see if this simple finger measurement could hint at hormonal exposure linked to cancer risk, but no treatment or diagnosis was tested.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Malatya Turgut Ozal University

    Malatya, Central, 44100, Turkey (Türkiye)

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If a link is found, finger ratios might become a simple, non-invasive clue to hormonal exposure and breast cancer risk, but this is very early and not a diagnostic tool.

What could go wrong

This is a small, completed observational study, not a treatment trial. Any association found may not be strong enough to be useful, and finger ratios are not a reliable way to diagnose or predict cancer.

Conditions

The condition(s) this trial relates to.

autosomal dominant medullary cystic kidney disease with or without hyperuricemia breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.